Results 71 to 80 of about 10,848 (199)

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab

Therapeutics and Clinical Risk Management, 2015
Arpita Shah Department of Pharmacy, Georgia Regents University Medical Center, Augusta, GA, USA Abstract: Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with a higher affinity for CD20 epitope, enhanced antibody-dependent
Shah A
doaj  

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Blood
Key Points • BOVen was safe and effective for the frontline treatment of TP53-mutant MCL.• The 2-year progression-free survival of 72% compares favorably with previously reported outcomes with chemoimmunotherapy in TP53-mutant MCL.
Anita Kumar, J. Soumerai, J. Abramson, Jeffrey A. Barnes, P. Caron, Shalini Chhabra, Maria Chabowska, A. Doğan, L. Falchi, C. Grieve, J. Haydu, P. Johnson, A. Joseph, Hailey E. Kelly, Alyssa Labarre, J. Lue, R. Martignetti, Joanna Mi, A. Moskowitz, C. Owens, S. Plummer, M. Puccio, G. Salles, V. Seshan, Elizabeth Simkins, N. Slupe, Hong-Lei Zhang, A. Zelenetz   +27 more
semanticscholar   +1 more source

Supplementary Figure S8 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

, 2021
Combination effect of rituximab plus doxorubicin or prednisolone in obinutuzumab resistant clones.
Yoriko Yamashita-Kashima (15088800), Natsumi Kawasaki (15088803), Yasushi Yoshimura (6553670), Shigeki Yoshiura (15088806), Naoki Harada (1822495), Takaaki Fujimura (15088797)   +5 more
core   +1 more source

Seizure improvement following intravenous immunoglobulin in drug‐resistant mesial temporal lobe epilepsy associated with systemic lupus erythematosus

Epileptic Disorders, EarlyView.
Kristijonas Puteikis, Basma Marzouk, Fabrice Bartolomei, Stanislas Lagarde   +3 more
wiley   +1 more source

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

Transfusion, EarlyView.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman, Meghana Vivek, Rida Hasan, Siobán Keel, Laura Connelly‐Smith   +4 more
wiley   +1 more source

B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think

Kidney Medicine
B-cell depletion with the chimeric anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of glomerular diseases. Obinutuzumab, a type II glycoengineered anti-CD20 humanized monoclonal antibody, is increasingly being employed as an ...
Decimo Silvio Chiarenza, Enrico E. Verrina, Carolina Bigatti, Gianluca Caridi, Agnese Spennacchio, Xhuliana Kajana, Massimiliano De Bortoli, Paolo Cravedi, Andrea Angeletti   +8 more
doaj   +1 more source

The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

AboutOpen, 2019
Introduction: Multicriteria Decision Analysis (MCDA) provides a framework that enhances transparency and repeatability of decisions taken on a multicriteria basis. Objective: This analysis aims at assessing obinutuzumab compared to rituximab used as a
Claudio Jommi, Roberto Ravasio
doaj   +1 more source

Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study

eJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
John M. Burke, Ira Zackon, Yunfei Wang, Kathleen M. Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Siyang Leng, Inkyu Kim, Diana Chirovsky, Enrico de Nigris   +10 more
wiley   +1 more source

Obinutuzumab [PDF]

Reactions Weekly, 2020
  +5 more sources

Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review

Frontiers in Pharmacology
BackgroundObinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL).
Chao Wang, Yunzhuo Dong, Peng Men, Ruixia Zhang, Ying Xiao, Yishan Bu, Yinpeng Qin, Xinran Zhang, Qianqian Dou, Yiheng Yang, Huier Gao, Yi Zhang   +11 more
doaj   +1 more source